Hindu Business Line reported Strides Pharma has filed a submission with the EMA for PTH® (proposed teriparatide biosimilar).
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Nov 03, 2020
Hindu Business Line reported Strides Pharma has filed a submission with the EMA for PTH® (proposed teriparatide biosimilar).
By Bioblast Editor | Nov 02, 2020
SBS News reported Federal Health Minister Greg Hunt announced the Government is close to securing two supply contracts for an additional two proposed COVID-19 vaccines. Additionally, Minister Hunt announced that PM Scott Morrison will present a plan for vaccine rollout to N...
By Naomi Pearce | Nov 02, 2020
Significant biosimilar activities this week include
22 Oct 20 | Ph III clinical trials of FYB202 (proposed ustekinumab biosimilar developed by Formycon and Bioeq) commenced recruiting in Poland.
26 Oct 20 | Samsung Bioepis announced results from two post-market...
By Bioblast Editor | Nov 02, 2020
Celltrion announces the results of Ph III studies of CT-P17 (proposed adalimumab biosimilar) demonstrate comparable efficacy and safety against reference adalimumab in rheumatoid arthritis.
By Bioblast Editor | Oct 31, 2020
Minister for Foreign Affairs Marise Payne announced the Australian Government has committed an additional $500 million over the next three years to supporting access to safe and effective COVID-19 vaccines for the Pacific and Southeast Asia region. This funding is additiona...
By Bioblast Editor | Oct 30, 2020
Ocumension Therapeutics announces it has reached an agreement with Shandong Boan Biological Technology to jointly develop OT-702, a proposed aflibercept biosimilar. Under the agreement, Ocumension has been granted an exclusive license to promote and commercialise the produc...
By Bioblast Editor | Oct 30, 2020
Ocumension Therapeutics announces it has reached an agreement with Shandong Boan Biological Technology to jointly develop OT-702, a proposed aflibercept biosimilar. Under the agreement, Ocumension has been granted an exclusive license to promote and commercialise the produc...
By Bioblast Editor | Oct 30, 2020
Fresenius Kabi receives a Notice of Compliance relating to its biosimilar adalimumab (50mg/mL), Idacio®.
By Bioblast Editor | Oct 29, 2020
SomaLogic announces it has signed an agreement with the FDA for the large-scale analysis of proteins for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar and a reference product. It is hoped that the five year colla...
By Bioblast Editor | Oct 29, 2020
SomaLogic announced it has signed an agreement with the FDA for the large-scale analysis of proteins for the identification of biomarkers that may be useful in demonstrating biosimilarity of a proposed biosimilar and a reference product. It is hoped that the five year colla...
SUBSCRIBE TO PEARCE IP